论文部分内容阅读
[目的]评价紫杉醇联合5-FU/FC治疗老年性晚期胃癌的疗效及安全性。[方法]入选者均病理证实为胃腺癌,紫杉醇175mg/m2ivgttd1,cf400mg/m2,5-fu400mg/m2ivd1,5fu3500mg/m2civ48h。每3周重复,治疗2周期判效。[结果]2001年1月~2006年12月共收治疗42例病人,41例可评价疗效及毒副作用,其中男性28例,女性13例,中位年龄65岁﹙60~82岁﹚初治37例,复治4例,治疗总周期数156周期,平均3.8周期,CR3例(占7.3%),PR15例(占36.6%),RR18例(占43.9%),SD15例(占36.5%),PD8例(占19.4%),病人受益率80.6%,TTP4.8月,中位生存12.3月。Ⅲ~Ⅳ级主要毒副作用为骨髓抑制WBC14.6%,PLT9.7%,HB7.3%,恶心呕吐7.3%,厌食9.7%,腹泻2.4%。[结论]本研究显示此方案治疗老年性晚期胃癌的疗效肯定且毒副作用可以耐受。
[Objective] To evaluate the efficacy and safety of paclitaxel combined with 5-FU / FC in the treatment of senile advanced gastric cancer. [Methods] All patients were pathologically confirmed gastric adenocarcinoma, paclitaxel 175mg / m2ivgttd1, cf400mg / m2, 5-fu400mg / m2ivd1, 5fu3500mg / m2civ48h. Repeat every 3 weeks for 2 cycles of treatment. [Results] From January 2001 to December 2006, 42 patients were treated and 41 patients were evaluated for their efficacy and side effects. Among them, 28 were males and 13 were females. The median age was 65 years old (60-82 years) 37 cases, retreatment in 4 cases, the total number of cycles of 156 cycles, an average of 3.8 cycles, CR3 cases (7.3%), PR15 cases (36.6%), RR18 cases (43.9%), SD15 cases (36.5% , PD8 cases (19.4%), the patient benefit rate was 80.6%, TTP4. August, the median survival of 12.3 months. Ⅲ ~ Ⅳ grade main side effects of bone marrow suppression WBC14.6%, PLT9.7%, HB7.3%, nausea and vomiting 7.3%, anorexia 9.7%, diarrhea 2.4%. [Conclusion] This study shows that the efficacy of this regimen in the treatment of elderly patients with advanced gastric cancer is affirmative and the side effects can be tolerated.